Marked Weight Loss, Muscle Wasting and Fatigue on Administration of Empagliflozin in a Subject with Type 2 Diabetes

Journal Title: Journal of Advances in Medicine and Medical Research - Year 2017, Vol 21, Issue 5

Abstract

Background: Weight loss, fatigue and decreased quality of life are frequently reported at the time of initial diagnosis by subjects with Diabetes Mellitus of both types although far more frequently with type 1 and are attributed to fluid and electrolyte losses due to persistent glycosuria as well as decline in adipose tissue secondary to lipolysis. However, muscle wasting and weakness as initial manifestations are noted almost exclusively in subjects with type 1 diabetes. Case Report: A man with history of type 2 diabetes about 10 years reported onset of general fatigue, polyuria, nocturia, polydipsia as well as profound progressive weight loss, muscle wasting and weakness within 2 weeks after initiation of Empagliflozin. He had been receiving glimepiride 8 mg and metformin 2000 mg daily for about 5.5 years. Resolution of polyuria, nocturia and polydipsia was attained promptly within a week after discontinuation of Empagliflozin and initiation of insulin glargine. Weight gain and improvement in fatigue began by 2 weeks, continued until achieving desirable glycemic control over next 4 months and then stabilized. However, muscle mass and strength have not yet returned to the level prior to initiation of Empagliflozin during the follow up period of 12 months. Conclusion: Empagliflozin is responsible for induction of transient weight loss as well as persistent muscle weakness and wasting in this subject.

Authors and Affiliations

Udaya M. Kabadi

Keywords

Related Articles

A Brief Review of Mucormycosis: Report of Five Cases

Mucormycosis is an emerging and slowly rising fatal infectious disease in most countries. It is the third most common invasive mycosis after candidiasis and aspergillosis. Hematologic malignancies notably acute myeloblas...

Association of Plasma Lead with Iron Indices and Complete Blood Count among Male Bricklayers in Ibadan, Oyo State

Background: Analysis of cement dust by various investigators has revealed that its contents include mercury (Hg), copper (Cu), chromium (Cr), cadmium (Cd), Nickel (Ni), Manganese (Mn) and lead (Pb). Few studies done amon...

Barriers, Facilitators, Strategies, and Predictors for Reporting Adverse Drug Reactions in three General Hospitals in Jeddah, 2013

Background: Adverse drug reactions (ADRs) are the main cause of significant morbidity and mortality worldwide. The identification of barriers, facilitators, strategies, and predictors for reporting ADRs helps in the prev...

Mother and Child Health Care and Human Development in Turkey: A Review

Human development and investing in human are major issues of today’s world. In spite of rapid improvements in the near past, Turkey is still behind of the most middle- income and of the countries at a similar level of ec...

Safety of Cupping Therapy in Studies Conducted in Twenty One Century: A Review of Literature

Background: Cupping therapy is a well-known traditional treatment modality, and has been used in various diseases around the world since ancient times. This method is reported to have a better clinical as well as adverse...

Download PDF file
  • EP ID EP311728
  • DOI 10.9734/BJMMR/2017/33253
  • Views 77
  • Downloads 0

How To Cite

Udaya M. Kabadi (2017). Marked Weight Loss, Muscle Wasting and Fatigue on Administration of Empagliflozin in a Subject with Type 2 Diabetes. Journal of Advances in Medicine and Medical Research, 21(5), 1-7. https://www.europub.co.uk/articles/-A-311728